Skip to main content

What the FDA labels say about taking them together

Cyclosporine and palbociclib

Palbociclib's FDA label of July 2, 2026 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name palbociclib. The palbociclib label: “The dose of the sensitive CYP3A substrate with a narrow therapeutic index may need to be reduced, as IBRANCE may increase its exposure.”

Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the palbociclib FDA label on DailyMed (effective July 2, 2026, Pfizer Laboratories Div Pfizer Inc).

What does the cyclosporine label say about palbociclib?

Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name palbociclib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed

What does the palbociclib label say about cyclosporine?

Palbociclib label, drug interactions

The dose of the sensitive CYP3A substrate with a narrow therapeutic index (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) may need to be reduced, as IBRANCE may increase its exposure [see Clinical Pharmacology (12.3) ].

Source: FDA drug label (Ibrance), Pfizer Laboratories Div Pfizer Inc, effective July 2, 2026 (SPL set fecbdd7d-b729-41b5-9872-231b8fe104ce), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

14Cyclosporine generic labelers
0Palbociclib generic labelers
CyclosporinePalbociclib
Labeled forOrgan transplant rejection, Rheumatoid arthritisBreast cancer
Boxed warningYesNo
Pharmacy cost (NADAC)$1.04 per unit 0.05% eye emulsionn/a
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?